Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Early adopters of GLP-1 drugs have now lost the weight and are beginning to transition off them. How can F&B support the ...

By screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent ...

Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

We recently published a list of Was Jim Cramer Right About These 13 Stocks? In this article, we are going to take a look at ...

Not long ago, the FDA announced there's no longer a shortage of Ozempic, Wegovy, Zepbound or similar drugs used for weight ...

Many employers are facing challenges in incorporating high-cost GLP-1 medications, such as Mounjaro, Ozempic, Rybelsus, Trulicity, and Wegovy, ...

Millions of Americans have tried GLP-1 medications like Ozempic, Mounjaro and Wegovy, polls show, but pharmacy claims data show that many people stop taking them within less than one year.

Some GLP-1 users also report fewer cravings for unhealthy ... The drugs in development now are dual agonists (like Mounjaro) and triple agonists, which activate multiple receptors simultaneously ...